Key result
Perioperative management of antiplatelet therapy after drug-eluting stent implantation remains controversial.
Why the study?
Does discontinuing antiplatelet therapy perioperatively increase risk in patients with drug-eluting stents?
Does discontinuing antiplatelet therapy perioperatively increase risk in patients with drug-eluting stents?
The optimal management of antiplatelet therapy during the perioperative period after DES implantation remains controversial.
Perioperative antiplatelet decisions after DES require individualized risk assessment; leaves open definitive guidance from prospective trials.
The optimal management of antiplatelet therapy during the perioperative period after drug-eluting stent (DES) implantation remains controversial and
No takes yet. Share an insight, caveat, or question.
Calderon et al. (2008) studied this question. Perioperative management of antiplatelet therapy after drug-eluting stent implantation remains controversial.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: